Drug-drug interaction associated with mold-active triazoles among hospitalized patients

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3398-3406

  Andes, David ^a   Azie, Nkechi ^b   Yang, Hongbo ^c   Harrington, Rachel ^b   Kelley, Caroline ^c   Tan, Ruo Ding ^c   Wu, Eric Q ^c   Franks, Billy ^b   Kristy, Rita ^b   Lee, Edward ^b   Khandelwal, Nikhil ^b   Spalding, James ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; AMLODIPINE; AZITHROMYCIN; CIPROFLOXACIN; CLOPIDOGREL; ESCITALOPRAM; ESOMEPRAZOLE; FENTANYL; FLUCONAZOLE; HALOPERIDOL; IBUPROFEN; ITRACONAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; MIDAZOLAM; OMEPRAZOLE; ONDANSETRON; OXYCODONE; PANTOPRAZOLE; POSACONAZOLE; PREDNISONE; PROCHLORPERAZINE; PROMETHAZINE; SIMVASTATIN; TACROLIMUS; TAMSULOSIN; UNINDEXED DRUG; VORICONAZOLE; WARFARIN; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG INFORMATION; DRUG POTENTIATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; DRUG INTERACTION; HOSPITALIZATION; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; HOSPITALIZATION; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; TRIAZOLES; VORICONAZOLE;

EID: 84973541017     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00054-16     Document Type: Article

References (33)

1. Lat A, Thompson GR, III. 2011. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 4:43-53. http://dx.doi.org/10.2147/IDR.S12714.
2. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo Clinic Proc 86:805-817. http://dx.doi.org/10.4065/mcp.2011.0247.
3. Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48:1441-1458. http://dx.doi.org/10.1086/598327.
4. Nivoix Y, Ubeaud-Sequier G, Engel P, Leveque D, Herbrecht R. 2009. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 10:395-409. http://dx.doi.org/10.2174/138920009788499012.
5. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. 2012. The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 73:293-300. http://dx.doi.org/10.1016/j.diagmicrobio.2012.06.012.
6. U.S. Food and Drug Administration. 2016. Preventable adverse drug reactions: a focus on drug interactions. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm.
7. Pergolizzi JV, Jr, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH. 2012. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract 12:45-56. http://dx.doi.org/10.1111/j.1533-2500.2011.00503.x.
8. Summers KH, Puenpatom RA, Rajan N, Ben-Joseph R, Ohsfeldt R. 2011. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ 14:390-396. http://dx.doi.org/10.3111/13696998.2011.583302.
9. Lubinga SJ, Uwiduhaye E. 2011. Potential drug-drug interactions on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors. Afr Health Sci 11:499-507.
10. Patel PS, Rana DA, Suthar JV, Malhotra SD, Patel VJ. 2014. A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. J Basic Clin Pharm 5:44-48. http://dx.doi.org/10.4103/0976-0105.134983.
11. Li AP. 1998. The scientific basis of drug-drug interactions: mechanism and preclinical evaluation. Drug Information J 32:657-664.
12. Bertoli R, Bissig M, Caronzolo D, Odorico M, Pons M, Bernasconi E. 2010. Assessment of potential drug-drug interactions at hospital discharge. Swiss Med Wkly 140:w13043. http://dx.doi.org/10.4414/smw.2010.13043.
13. Egger SS, Drewe J, Schlienger RG. 2003. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58:773-778.
14. Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. 2005. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 14:755-767. http://dx.doi.org/10.1002/pds.1073.
15. Andes D. 2013. Optimizing antifungal choice and administration. Curr Med Res Opin 29(Suppl 4):S13-S18. http://dx.doi.org/10.1185/03007995.2012.761135.
16. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. 2004. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76:85-96. http://dx.doi.org/10.1016/j.clpt.2004.02.009.
17. Micromedex. Micromedex healthcare series. Micromedex, Greenwood Village, CO.
18. U.S. Food and Drug Administration. 2001. Drug approval package. Sporanox (itraconazole) injection & oral solution. U.S. Food and Drug Administration, Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2001/20-966S001-Sporanox.cfm. Accessed 29 January 2016.
19. U.S. Food and Drug Administration. 2006. Drug approval package. Noxafil (posaconazole) oral suspension. U.S. Food and Drug Administration, Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/022027-noxafil-toc.cfm. Accessed 29 January 2016.
20. U.S. Food and Drug Administration. 2002. Drug approval package. Vfend (voriconazole) tablets & injection. U.S. Food and Drug Administration, Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2002/21-266-21-267-Vfend.cfm. Accessed 29 January 2016.
21. Hammann F, Drewe J. 2014. Data mining for potential adverse drug-drug interactions. Expert Opin Drug Metab Toxicol 10:665-671. http://dx.doi.org/10.1517/17425255.2014.894507.
22. Gubbins PO. 2011. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. Expert Opin Drug Metab Toxicol 7:1411-1429. http://dx.doi.org/10.1517/17425255.2011.627854.
23. Dodds-Ashley E. 2010. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 30:842-854. http://dx.doi.org/10.1592/phco.30.8.842.
24. U.S. Food and Drug Administration. 2009. Pharmacology review(s). Application number 22-484. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022484Orig1s000PharmR.pdf. Accessed 29 January 2016.
25. Gallagher JC, Dodds Ashley ES, Drew RH, Perfect JR. 2003. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 4:147-164. http://dx.doi.org/10.1517/14656566.4.2.147.
26. Carrillo-Munoz AJ, Quindos G, Ruesga M, Alonso R, del Valle O, Hernández-Molina JM, McNicholas P, Loebenberg D, Santos P. 2005. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55:317-319. http://dx.doi.org/10.1093/jac/dki022.
27. Aypar E, Kendirli T, Tutar E, Ciftçi E, Ince E, Ileri T, Atalay S. 2011. Voriconazole-induced QT interval prolongation and torsades de pointes. Pediatr Int 53:761-763. http://dx.doi.org/10.1111/j.1442-200X.2010.03321.x.
28. Elbey MA, Cil H, Onturk E, Islamoglu Y. 2012. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy. Eur Rev Med Pharmacol Sci 16:100-102.
29. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, Graham DR, Greenberg RN, Hadley S, Langston A, Negroni R, Perfect JR, Pitisuttithum P, Restrepo A, Schiller G, Pedicone L, Ullmann AJ. 2006. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 42:1726-1734. http://dx.doi.org/10.1086/504328.
30. Zeuli JD, Wilson JW, Estes LL. 2013. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents Chemother 57:1121-1127. http://dx.doi.org/10.1128/AAC.00958-12.
31. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. 2004. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis 39:e49-e52. http://dx.doi.org/10.1086/423275.
32. Hachem RY, Langston AA, Graybill JR, Perfect JR, Pedicone LD, Patino H, Raad II. 2008. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 62:1386-1391. http://dx.doi.org/10.1093/jac/dkn401.
33. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. 2006. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570-1572. http://dx.doi.org/10.1128/AAC.50.4.1570-1572.2006.